Literature DB >> 33593356

Uric acid-induced pancreatic β-cell dysfunction.

Asghar Ghasemi1.   

Abstract

Hyperuricemia is associated with insulin resistance, pancreatic β-cell dysfunction and consequently with development of type 2 diabetes. Although a direct relationship between high levels of uric acid (UA) and the development of diabetes is still a controversial issue, there is some evidence that strongly points to pancreatic β-cells damage as a result of high serum UA levels. Here, the mechanisms underlying UA-induced β-cell damage are discussed. Available literature indicates that UA can decrease glucose-stimulated insulin secretion and cause β-cell death. The mechanisms underlying these effects are UA-induced oxidative stress and inflammation within the β-cells. UA also stimulates inducible nitric oxide (NO) synthase (iNOS) gene expression leading to NO-induced β-cell dysfunction. Thus hyperuricemia may potentially cause β-cell dysfunction, leading to diabetes. It may be hypothesized that in hyperuricemic subjects, UA-lowering drugs may be beneficial in preventing diabetes.

Entities:  

Keywords:  Nitric oxide; Pancreatic β-cell; Type 2 diabetes; Uric acid

Year:  2021        PMID: 33593356     DOI: 10.1186/s12902-021-00698-6

Source DB:  PubMed          Journal:  BMC Endocr Disord        ISSN: 1472-6823            Impact factor:   2.763


  53 in total

Review 1.  Type 2 diabetes: A 21st century epidemic.

Authors:  Lindsay M Jaacks; Karen R Siegel; Unjali P Gujral; K M Venkat Narayan
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-05-28       Impact factor: 4.690

Review 2.  Regulation of uric acid metabolism and excretion.

Authors:  Jessica Maiuolo; Francesca Oppedisano; Santo Gratteri; Carolina Muscoli; Vincenzo Mollace
Journal:  Int J Cardiol       Date:  2015-08-14       Impact factor: 4.164

Review 3.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

4.  Decreased incidence of diabetes in patients with gout using benzbromarone.

Authors:  Sheng-Wen Niu; Kai-Ting Chang; Albert Ta; Yu-Han Chang; I Ching Kuo; Chi-Chih Hung; Yi-Wen Chiu; Shang-Jyh Hwang; Sheng-Fung Lin; Hugo You-Hsien Lin
Journal:  Rheumatology (Oxford)       Date:  2018-09-01       Impact factor: 7.580

5.  IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

Authors:  N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda
Journal:  Diabetes Res Clin Pract       Date:  2018-02-26       Impact factor: 5.602

Review 6.  Uric acid and cardiovascular disease.

Authors:  Gjin Ndrepepa
Journal:  Clin Chim Acta       Date:  2018-05-24       Impact factor: 3.786

Review 7.  Uric acid transport and disease.

Authors:  Alexander So; Bernard Thorens
Journal:  J Clin Invest       Date:  2010-06-01       Impact factor: 14.808

8.  High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors.

Authors:  Ravi Suppiah; Ajith Dissanayake; Nicola Dalbeth
Journal:  N Z Med J       Date:  2008-10-03

Review 9.  Pancreatic β-cell identity, glucose sensing and the control of insulin secretion.

Authors:  Guy A Rutter; Timothy J Pullen; David J Hodson; Aida Martinez-Sanchez
Journal:  Biochem J       Date:  2015-03-01       Impact factor: 3.857

Review 10.  Physiological functions and pathogenic potential of uric acid: A review.

Authors:  Rashika El Ridi; Hatem Tallima
Journal:  J Adv Res       Date:  2017-03-14       Impact factor: 10.479

View more
  6 in total

1.  Prediction model of random forest for the risk of hyperuricemia in a Chinese basic health checkup test.

Authors:  Yuhan Gao; Shichong Jia; Dihua Li; Chao Huang; Zhaowei Meng; Yan Wang; Mei Yu; Tianyi Xu; Ming Liu; Jinhong Sun; Qiyu Jia; Qing Zhang; Ying Gao; Kun Song; Xing Wang; Yaguang Fan
Journal:  Biosci Rep       Date:  2021-04-30       Impact factor: 3.840

Review 2.  New Insights into the Efficacy of Aspalathin and Other Related Phytochemicals in Type 2 Diabetes-A Review.

Authors:  Christo J F Muller; Elizabeth Joubert; Nireshni Chellan; Yutaka Miura; Kazumi Yagasaki
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

3.  Pharmacodynamic evaluation of the XOR inhibitor WN1703 in a model of chronic hyperuricemia in rats induced by yeast extract combined with potassium oxonate.

Authors:  Yuanyuan Li; Xinying Zhu; Fuyao Liu; Wen Peng; Lei Zhang; Jing Li
Journal:  Curr Res Pharmacol Drug Discov       Date:  2022-03-27

4.  Allopurinol Use and the Risk of Type 2 Diabetes Mellitus: A Meta-Analysis of Cohort Studies.

Authors:  Shih-Wei Lai; Bing-Fang Hwang; Yu-Hung Kuo; Chiu-Shong Liu; Kuan-Fu Liao
Journal:  Dose Response       Date:  2022-09-07       Impact factor: 2.623

Review 5.  Hyperuricemia-induced endothelial insulin resistance: the nitric oxide connection.

Authors:  Zahra Bahadoran; Parvin Mirmiran; Khosrow Kashfi; Asghar Ghasemi
Journal:  Pflugers Arch       Date:  2021-07-27       Impact factor: 3.657

6.  Protective Effects of Astragaloside IV on Uric Acid-Induced Pancreatic β-Cell Injury through PI3K/AKT Pathway Activation.

Authors:  Zhenhuan Jiang; Gang Wang; Lingling Meng; Yunzhao Tang; Min Yang; Changlin Ni
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-10       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.